<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02541955</url>
  </required_header>
  <id_info>
    <org_study_id>Acthar in Rheumatoid Arthritis</org_study_id>
    <nct_id>NCT02541955</nct_id>
  </id_info>
  <brief_title>Use of Acthar in Rheumatoid Arthritis (RA) Related Flares</brief_title>
  <official_title>Use of Acthar in Rheumatoid Arthritis Related Flares</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Veena Ranganath</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Rheumatoid Arthritis (RA) study. The purpose of this research study is to determine
      in RA flare, whether musculoskeletal ultrasound (MSUS) inflammatory scores and/or disease
      activity scores improve with Acthar treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with active RA flair will be assigned to take on one of two Acthar doses, either
      40 units per week or 80 units twice a week. Both arms will be taking the drug for 4 weeks.
      Each participant will be coming back for visits at 2 weeks, 1 month and 3 months after the
      initial baseline visit. During these visits the following information will be collected: MSUS
      of joints, DAS28, Clinical Disease Activity Index (CDAI), Routine Assessment of Patient Index
      Data 3 (RAPID3) and Health Assessment Questionnaire-Disability Index (HAQ-DI). Participants
      will also be asked to fill out a questionnaire about their health status.

      Efficacy of Acthar to decrease evidence of MSUS synovitis and disease activity measures will
      be analyzed using the above mentioned instruments, as well as Acthar's ability to prevent the
      necessity to change patients' RA treatment regimen.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ultrasound Power Doppler Score</measure>
    <time_frame>Baseline to 2 Weeks</time_frame>
    <description>Using Ultrasound a measure of Power Doppler will be calculated. The change in the scores will be analyzed between the two groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DAS28</measure>
    <time_frame>Baseline to 2 Weeks</time_frame>
    <description>DAS28 will be calculated. The change in the scores will be analyzed between the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ultrasound Grey Scale Synovial Hypertrophy score</measure>
    <time_frame>Baseline to 2 Weeks</time_frame>
    <description>Using Ultrasound a measure of Grey Scale Synovial Hypertrophy will be calculated. The change in the scores will be analyzed between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAQ-DI</measure>
    <time_frame>Baseline to 4 Weeks</time_frame>
    <description>Self-administered HAQ-DI summary score will be calculated. The change in the scores will be analyzed between the two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>40 Units</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 units of Acthar per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 Units</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80 units of Acthar twice per week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar</intervention_name>
    <description>Injections will be self administered</description>
    <arm_group_label>40 Units</arm_group_label>
    <arm_group_label>80 Units</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient must meet 1987 ACR criteria

          2. Age &gt; 18 years of age

          3. Baseline DAS28/Erythrocyte Sedimentation Rate (ESR) &gt;=3.2

          4. Stable concomitant Disease Modifying Anti-Rheumatic Drugs (DMARDs)

          5. Stable prednisone &lt;10mg or equivalent

          6. Power Doppler score of &gt;=10

        Exclusion Criteria:

          1. Prior treatment with Acthar in the past 2mos

          2. Meet one of the above RA flare requirements

          3. Subjects who have received live or live attenuated vaccines within 6 weeks prior to
             the first dose of study drug (or the zoster vaccine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veena K Ranganath, M.D., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veena K Rangantah, M.D., M.S.</last_name>
    <phone>310-825-3061</phone>
    <email>vranganath@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bal-lan Yen</last_name>
    <phone>310-206-4112</phone>
    <email>byen@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine, Division of Rheumatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veena K Ranganath, M.D.</last_name>
      <phone>310-825-6301</phone>
      <email>vranganath@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Veena K Ranganath, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suzanne Kafaja, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Dr. Veena Ranganath</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid arthritis (RA)</keyword>
  <keyword>Musculoskeletal ultrasound (MSUS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

